Shots:
An equity hedge fund manager company, BVF Partners invests in small cap and early-stage biotechnology companies
In 2023, BVF participated in five investment rounds and added 20 companies to its portfolio
For a curated report on a specific investor or venture capital, reach out to us at connect@pharmashots.com
Established in 1993 in San Francisco, California,…
Shots:
With more than 50 percent of ongoing clinical trials, Oncology remains one of the most explored therapy areas in healthcare
In 2023, the global oncology market was valued at $222.36B and is envisioned to grow to $521.6B by 2033, registering a CAGR of 8.9% from 2024 to 2033. With $27.6B registered oncology revenue, Merck…
Shots:
Gaucher disease is a rare, autosomal recessive disorder that enlarges organs like the bone marrow, liver, and spleen by depositing fats (lipids) in them
In this reprise of our Disease of the Month report, we present an enlightening description of Gaucher disease with a thorough study of epidemiology, market size, disease management, potential medicines,…
Shots:
Research & Development (R&D) plays an instrumental role in paving the foundation for innovative therapeutic options in the healthcare sector
The global Top 20 pharmaceutical industry spent $148B in 2022 and grew to $180B in 2023, with Merck & Co., had the highest R&D expenditure of $30.53B, followed by Roche ($15.73) and Johnson &…
Shots:
In the August Edition of the Know Your Investor series, we bring a condensed yet illuminating report on Arch Venture Partners
In 2023, Arch Ventures Partners participated in 6 investment rounds and added 27 companies focusing on biopharma and manufacturing & services to its portfolio
For a detailed report on all the investments, reach…
Shots:
Immunology remains one of the most explored therapy areas. Companies focusing on immunology are steadfastly working to advance treatment options by developing drugs, vaccines, and antibodies
In 2023, the global immunology market size was valued at $98.22B and expected to register $263.22B by 2033, with a CAGR of 10.36% from 2024 to 2033. AbbVie…
Shots:
Backed with an evergreen investment strategy, Invus makes investments across several company stages ranging from early growth to turnarounds
In 2023, Invus participated in 6 investment rounds in around 29 companies focusing on biopharma, manufacturing & services, and devices
For a curated report on a specific investor or venture capital, reach out to us…
Shots:
Vaccines play an instrumental role in curbing infectious diseases by generating antibodies against antigens and creating a memory to defeat them. Several biopharma companies are steadfastly working to deliver vaccines against infectious and vaccine-preventable diseases around the world
In 2024, the global vaccine market is estimated to be around $78B and is expected to…
Shots:
New-age technologies are transforming the healthcare industry continuously. By leveraging digital health platforms, AI-powered apps, and other innovative solutions, there is a significant enhancement in diagnosis, treatment, and prevention
With a global market revenue of $180.2B in 2023, the market is projected to reach $549.7B by 2028, registering a CAGR of 25 percent. This…
Shots:
Google Ventures is an investment arm of Alphabet Inc. That invests profusely in seed-stage companies ranging from software and internet to healthcare, life sciences, and artificial intelligence among others
Ever since 2016, GV pivoted to focusing on established companies. The company manages assets worth $10B and 400 active portfolio companies spanning across North America…

